Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Carotid artery stent trials show positive three-year results

Boston Scientific : 24 October, 2007  (New Product)
Positive three-year results from the Cabernet and Beach carotid artery stenting clinical trials has been announced by Boston Scientific.
The studies evaluated the effectiveness of stenting with embolic protection
for patients at high risk for carotid endarterectomy (CEA), the surgical
treatment for carotid artery disease.

The three-year Cabernet and Beach results were presented by L Nelson Hopkins, MD, chairman of neurosurgery, Department of Neurosurgery, State University of New York, Buffalo, NY, USA, at the annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, DC, USA.

Dr Hopkins reported that the Cabernet major stroke rate was 1.3 percent at 30 days and 2.8 percent at three years. The reported Beach major stroke rate was 1.7 percent at 30 days and 8.1 percent at three years.

According to the three-year Cabernet data, the ipsilateral stroke rate (a stroke occurring on the treated side of the neck) was 2.9 percent at 30 days and by three years had only increased to 4.9 percent. In the Beach trial, the ipsilateral stroke rate was 3.1 per cent at 30 days and by three years had only increased to 7.7 percent.

'The three-year results suggest not only an immediate benefit for patients treated with Boston Scientific's NexStent Carotid Stent and FilterWire EZ Embolic Protection System, but also a longer-term benefit in reducing the incidence of stroke over time,' said Dr Hopkins, co-principal investigator of the Cabernet and Beach clinical trials.

'In particular, the Cabernet three-year trial results are very encouraging and continue to demonstrate the long-term efficacy and durability associated with Boston Scientific's NexStent Carotid Stent when used with the company's FilterWire EZ Embolic Protection System in treating patients at high risk for carotid endarterectomy.'

The Cabernet clinical trial was designed to evaluate the safety and efficacy of Boston Scientific's NexStent Carotid Stent and FilterWire EZ Embolic Protection System, while the Beach clinical trial was designed to evaluate the safety and efficacy of the Company's Carotid Wallstent Monorail Endoprosthesis and FilterWire EZ Embolic Protection System.

Cabernet and Beach were both prospective, non-randomised, single-arm clinical trials enrolling 454 patients and 480 patients, respectively, who were at high risk for CEA.

'We continue to be excited about the favourable results being reported from the Cabernet and Beach trials now out to three years,' said John Pedersen, president of Peripheral Interventions of Boston Scientific.

'The three-year data provide further evidence of the benefits of the NexStent Carotid Stent and FilterWire EZ Embolic Protection System in treating patients at risk for stroke, as well as the potential clinical benefits of Carotid Wallstent Endoprosthesis. These trials are indicative of our commitment as a company to evaluate the long-term safety and efficacy of our products in treating carotid artery disease.'

The NexStent Carotid Stent is a closed cell, nitinol Stent with a rolled sheet design that enables one Stent size to adapt to multiple diameters in tapered or non-tapered vessel configurations. The Carotid Wallstent Endoprosthesis is a self-expanding Stent with a braided, closed cell design.

Closed-cell configurations are designed to increase lesion coverage and provide a smooth inner lumen to help facilitate delivery and retrieval of ancillary devices. The FilterWire EZ System - an advanced technology designed for simplicity and effectiveness - captures debris efficiently, simplifies filter sizing and is easy to deliver and retrieve. When compared to surgical alternatives, this system provides a less-invasive way to treat patients with carotid artery disease.

The US FDA has approved the NexStent Carotid Stent and FilterWire EZ Embolic Protection System for use in patients with carotid artery disease who are at high risk for CEA. The Carotid Wallstent Endoprosthesis is an investigational device currently under FDA review and is subject to investigational use only under US Federal law.

Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo